Fut, nem toboroz3. fázis
STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS
A legfontosabb adatok
- Ki végzi
- Istituto Giannina Gaslini
- Hol
- Olaszország20 helyszín, 1 országbanVálassz országot a helyszínekhez
- Állapot
- Fut, nem toboroz
- Fázis
- 3. fázis
- Résztvevők
- 260 fő, tervezett
- Kezdés
- 2019. máj. 29.
- Várható befejezés
- 2026. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
- A vizsgált kezelések
- Etanercept
- Methotrexate
- Intra-articular corticosteroid injections
- A regiszteradat frissítve
- 2026. november 17.
Ki vehet részt
- Életkor
- 2 év – 17 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 24 feltétel megnézéseKevesebb
Ki vehet részt
- Each patient must meet all the following criteria in order to be enrolled in the trial:
- Newly-diagnosed and synthetic or biologic DMARD-naïve children (only treatment with 1 NSAID is allowed and no corticosteroid joint injections prior to randomization ) with a JIA classified according to the following ILAR categories:
- Oligoarthritis ii. Rheumatoid factor negative polyarthritis
- Active arthritis
- Onset of JIA symptoms no more than 6 months before randomization
- Age 2 to 17 years at enrolment
- Female of child-bearing potential must have a negative pregnancy test at the beginning of the trial. If sexually active, they must agree to use highly effective contraceptive measures, throughout study participation, and must have no intention of conceiving during the course of the study. Post-pubertal males must have no plans to father a child during the study and agree to use highly effective contraceptive measures if sexually active
- Ability to comply with the entire study procedures, ability to communicate meaningfully with the investigational staff, competence to give written informed consent; to be applied to the parents and/or patients, as appropriate
- Duly executed, written, informed consent/assent obtained from the parents/patient
Ki nem vehet részt
- PPD or QuantiFERON-TB positive patients (with no active disease) unless it is documented by a specialist that the patient has been adequately treated for TB and can start treatment with a biologic agent, based on the medical judgment of the study investigator and / or an infectious disease specialist
- Previous treatment with any synthetic or biologic DMARD
- Any live attenuated vaccine within 4 weeks prior to the baseline visit, such as varicella-zoster, oral polio, measles, mumps or rubella vaccines and throughout the study. Killed or inactive vaccine may be permitted based on the investigator's judgment
- Tuberculosis related issues: patients are excluded from the study if they have:
- Active TB or a history of incompletely treated TB
- Suspected extrapulmonary TB infection
- Prior or current history of malignancy or any other significant concomitant illness(es) as per the treating physician evaluation
- Any of the following laboratory abnormalities based on the most recent laboratory results:
- White blood cell (WBC) count <3.50 x 103/mm3 (SI units: <3.50 x 109/L) and neutrophils < 1x109/L
- Hemoglobin < 8.5 g/dL (SI units: <85 g/L)
- Platelet Count < 125,0000/mm3 or ≥1,000,000/mm3 (SI units: <125 x 109/L or ≥1,000 x 109/L
- Aspartate aminotransaminase (AST) or alanine aminotransaminase (ALT) ≥ 2.0 x upper limit of normal (ULN)
- Classification in one of the following JIA categories: systemic arthritis, RF-positive polyarthritis, psoriatic arthritis, enthesitis-related arthritis, undifferentiated arthritis
- Patients who need systemic treatment for uveitis
- Patients at high risk of contracting TB, such as close contact with individual with active or latent TB
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study aims to compare the effectiveness of a conventional therapeutic regimen, based on treatment escalation (step-up strategy) and driven by the treat-to-target approach, with that of an early aggressive intervention based on the initial start of a combination of conventional and biological DMARDs (step-down strategy).
A vizsgálat 2 csoportja
- Treatment arm 1: Step-upNincs vizsgálati kezelés, összehasonlításként
JIA patients managed with a Treat-To-Target strategy (T2T)
- Treatment arm 2: Step-downA vizsgált kezelés
JIA patients treated with an early combined therapy
Kezelés: Etanercept, Methotrexate és Intra-articular corticosteroid injections
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- Comparison of STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS
- Publikációk
- Methotrexate for juvenile idiopathic arthritis.The Cochrane database of systematic reviews, 2024
- Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the "comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS" (STARS) trial.Pediatric rheumatology online journal, 2022
- A regiszteradat frissítve
- 2026. november 17.